Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1297 to 1307 of 1307 entries
Sorted by: Best Match Show Resources per page
Apixaban in low-weight patients with cancer-associated thrombosis: A cross sectional study of drug levels.

Research and practice in thrombosis and haemostasis

Bravo Villa V, Romero J, Rojas-Zaldivar E, Cervantes M, Villa-Márquez MDR, Baz P, Cesarman-Maus G.
PMID: 33870027
Res Pract Thromb Haemost. 2021 Mar 23;5(3):421-425. doi: 10.1002/rth2.12492. eCollection 2021 Mar.

INTRODUCTION: Apixaban, a direct factor Xa inhibitor, has been shown to be at least as safe and probably more effective than dalteparin for the treatment of cancer-associated thrombosis (CAT) as reported in the ADAM-VTE and Caravaggio studies, which included...

Cite
Bravo Villa V, Romero J, Rojas-Zaldivar E, et al. Apixaban in low-weight patients with cancer-associated thrombosis: A cross sectional study of drug levels. Res Pract Thromb Haemost. 2021;5(3):421-425doi: 10.1002/rth2.12492.
Bravo Villa, V., Romero, J., Rojas-Zaldivar, E., Cervantes, M., Villa-Márquez, M. D. R., Baz, P., & Cesarman-Maus, G. (2021). Apixaban in low-weight patients with cancer-associated thrombosis: A cross sectional study of drug levels. Research and practice in thrombosis and haemostasis, 5(3), 421-425. https://doi.org/10.1002/rth2.12492
Bravo Villa, Verónica, et al. "Apixaban in low-weight patients with cancer-associated thrombosis: A cross sectional study of drug levels." Research and practice in thrombosis and haemostasis vol. 5,3 (2021): 421-425. doi: https://doi.org/10.1002/rth2.12492
Bravo Villa V, Romero J, Rojas-Zaldivar E, Cervantes M, Villa-Márquez MDR, Baz P, Cesarman-Maus G. Apixaban in low-weight patients with cancer-associated thrombosis: A cross sectional study of drug levels. Res Pract Thromb Haemost. 2021 Mar 23;5(3):421-425. doi: 10.1002/rth2.12492. eCollection 2021 Mar. PMID: 33870027; PMCID: PMC8035794.
Copy Download .nbib Format: NLM
Patient selection for hemophilia gene therapy: Real-life data from a single center.

Research and practice in thrombosis and haemostasis

Krumb E, Lambert C, Hermans C.
PMID: 33870024
Res Pract Thromb Haemost. 2021 Mar 14;5(3):390-394. doi: 10.1002/rth2.12494. eCollection 2021 Mar.

BACKGROUND: While the number of individuals with hemophilia who are expected to be or have already been included in gene therapy trials has been regularly reported, the number of unscreened or excluded individuals, in addition to the reasons for...

Cite
Krumb E, Lambert C, Hermans C. Patient selection for hemophilia gene therapy: Real-life data from a single center. Res Pract Thromb Haemost. 2021;5(3):390-394doi: 10.1002/rth2.12494.
Krumb, E., Lambert, C., & Hermans, C. (2021). Patient selection for hemophilia gene therapy: Real-life data from a single center. Research and practice in thrombosis and haemostasis, 5(3), 390-394. https://doi.org/10.1002/rth2.12494
Krumb, Evelien, et al. "Patient selection for hemophilia gene therapy: Real-life data from a single center." Research and practice in thrombosis and haemostasis vol. 5,3 (2021): 390-394. doi: https://doi.org/10.1002/rth2.12494
Krumb E, Lambert C, Hermans C. Patient selection for hemophilia gene therapy: Real-life data from a single center. Res Pract Thromb Haemost. 2021 Mar 14;5(3):390-394. doi: 10.1002/rth2.12494. eCollection 2021 Mar. PMID: 33870024; PMCID: PMC8035793.
Copy Download .nbib Format: NLM
Exploring the utility of a novel point-of-care whole blood thrombin generation assay following trauma: A pilot study.

Research and practice in thrombosis and haemostasis

Ferrara MJ, MacArthur TA, Butenas S, Mann KG, Immermann JM, Spears GM, Bailey KR, Kozar RA, Heller SF, Loomis EA, Stephens D, Park MS.
PMID: 33870025
Res Pract Thromb Haemost. 2021 Mar 08;5(3):395-402. doi: 10.1002/rth2.12483. eCollection 2021 Mar.

INTRODUCTION: Plasma thrombin generation kinetics as measured by the calibrated automated thrombogram (CAT) assay is a predictor of symptomatic venous thromboembolism after trauma. We hypothesized that data from a new prototype assay for measurement of thrombin generation kinetics in...

Cite
Ferrara MJ, MacArthur TA, Butenas S, et al. Exploring the utility of a novel point-of-care whole blood thrombin generation assay following trauma: A pilot study. Res Pract Thromb Haemost. 2021;5(3):395-402doi: 10.1002/rth2.12483.
Ferrara, M. J., MacArthur, T. A., Butenas, S., Mann, K. G., Immermann, J. M., Spears, G. M., Bailey, K. R., Kozar, R. A., Heller, S. F., Loomis, E. A., Stephens, D., & Park, M. S. (2021). Exploring the utility of a novel point-of-care whole blood thrombin generation assay following trauma: A pilot study. Research and practice in thrombosis and haemostasis, 5(3), 395-402. https://doi.org/10.1002/rth2.12483
Ferrara, Michael J, et al. "Exploring the utility of a novel point-of-care whole blood thrombin generation assay following trauma: A pilot study." Research and practice in thrombosis and haemostasis vol. 5,3 (2021): 395-402. doi: https://doi.org/10.1002/rth2.12483
Ferrara MJ, MacArthur TA, Butenas S, Mann KG, Immermann JM, Spears GM, Bailey KR, Kozar RA, Heller SF, Loomis EA, Stephens D, Park MS. Exploring the utility of a novel point-of-care whole blood thrombin generation assay following trauma: A pilot study. Res Pract Thromb Haemost. 2021 Mar 08;5(3):395-402. doi: 10.1002/rth2.12483. eCollection 2021 Mar. PMID: 33870025; PMCID: PMC8035795.
Copy Download .nbib Format: NLM
Updating the Canadian Hemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) in the era of extended half-life clotting factor concentrates.

Research and practice in thrombosis and haemostasis

Price VE, Dover S, Blanchette VS, Klaassen RJ, Belletrutti M, Bruce AAK, Chan AK, Wakefield C, Carcao M, Bouskill V, Young NL.
PMID: 33870026
Res Pract Thromb Haemost. 2021 Mar 27;5(3):403-411. doi: 10.1002/rth2.12498. eCollection 2021 Mar.

INTRODUCTION: The purpose of this study was to review and update the content of the Canadian Hemophilia Outcomes-Kids' Life Assessment Tool version 2.0 (CHO-KLAT), in the context of extended half-life (EHL) factor concentrates (FCs) and to establish the validity...

Cite
Price VE, Dover S, Blanchette VS, et al. Updating the Canadian Hemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) in the era of extended half-life clotting factor concentrates. Res Pract Thromb Haemost. 2021;5(3):403-411doi: 10.1002/rth2.12498.
Price, V. E., Dover, S., Blanchette, V. S., Klaassen, R. J., Belletrutti, M., Bruce, A. A. K., Chan, A. K., Wakefield, C., Carcao, M., Bouskill, V., & Young, N. L. (2021). Updating the Canadian Hemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) in the era of extended half-life clotting factor concentrates. Research and practice in thrombosis and haemostasis, 5(3), 403-411. https://doi.org/10.1002/rth2.12498
Price, Victoria E, et al. "Updating the Canadian Hemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) in the era of extended half-life clotting factor concentrates." Research and practice in thrombosis and haemostasis vol. 5,3 (2021): 403-411. doi: https://doi.org/10.1002/rth2.12498
Price VE, Dover S, Blanchette VS, Klaassen RJ, Belletrutti M, Bruce AAK, Chan AK, Wakefield C, Carcao M, Bouskill V, Young NL. Updating the Canadian Hemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) in the era of extended half-life clotting factor concentrates. Res Pract Thromb Haemost. 2021 Mar 27;5(3):403-411. doi: 10.1002/rth2.12498. eCollection 2021 Mar. PMID: 33870026; PMCID: PMC8035800.
Copy Download .nbib Format: NLM
On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome.

Thrombosis and haemostasis

Laine M, Panagides V, Frère C, Cuisset T, Gouarne C, Jouve B, Lemesle G, Paganelli F, Alessi MC, Mancini J, Bonello L.
PMID: 33260230
Thromb Haemost. 2021 Jul;121(7):923-930. doi: 10.1055/a-1326-5110. Epub 2020 Dec 01.

BACKGROUND:  A strong association between on-thienopyridine platelet reactivity (PR) and the risk of both thrombotic and bleeding events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) has been demonstrated. However, no study has analyzed the relationship...

Cite
Laine M, Panagides V, Frère C, et al. On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. Thromb Haemost. 2020;121(7):923-930doi: 10.1055/a-1326-5110.
Laine, M., Panagides, V., Frère, C., Cuisset, T., Gouarne, C., Jouve, B., Lemesle, G., Paganelli, F., Alessi, M. C., Mancini, J., & Bonello, L. (2021). On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. Thrombosis and haemostasis, 121(7), 923-930. https://doi.org/10.1055/a-1326-5110
Laine, Marc, et al. "On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome." Thrombosis and haemostasis vol. 121,7 (2021): 923-930. doi: https://doi.org/10.1055/a-1326-5110
Laine M, Panagides V, Frère C, Cuisset T, Gouarne C, Jouve B, Lemesle G, Paganelli F, Alessi MC, Mancini J, Bonello L. On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. Thromb Haemost. 2021 Jul;121(7):923-930. doi: 10.1055/a-1326-5110. Epub 2020 Dec 01. PMID: 33260230.
Copy Download .nbib Format: NLM
Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect?.

Thrombosis and haemostasis

Vera A, Rivero F, Salamanca J, Alvarado-Casas T, Alfonso F.
PMID: 33260247
Thromb Haemost. 2021 Jul;121(7):976-978. doi: 10.1055/a-1326-7028. Epub 2020 Dec 01.

The current article describes a 72-year-old woman who suffered an acute myocardial infarction due to plaque erosion (PE) 2 weeks after abemaciclib treatment onset due to advanced breast cancer. Abemaciclib is a cyclin-dependent kinase 4 and 6 inhibitor that...

Cite
Vera A, Rivero F, Salamanca J, et al. Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect?. Thromb Haemost. 2020;121(7):976-978doi: 10.1055/a-1326-7028.
Vera, A., Rivero, F., Salamanca, J., Alvarado-Casas, T., & Alfonso, F. (2021). Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect?. Thrombosis and haemostasis, 121(7), 976-978. https://doi.org/10.1055/a-1326-7028
Vera, Alberto, et al. "Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect?." Thrombosis and haemostasis vol. 121,7 (2021): 976-978. doi: https://doi.org/10.1055/a-1326-7028
Vera A, Rivero F, Salamanca J, Alvarado-Casas T, Alfonso F. Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect?. Thromb Haemost. 2021 Jul;121(7):976-978. doi: 10.1055/a-1326-7028. Epub 2020 Dec 01. PMID: 33260247.
Copy Download .nbib Format: NLM
Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen.

Thrombosis and haemostasis

Bukkems LH, Fischer K, Kremer-Hovinga I, Donners AAM, Fijnvandraat K, Schutgens REG, Cnossen MH, Mathôt RAA.
PMID: 33946119
Thromb Haemost. 2021 May 04; doi: 10.1055/a-1499-0030. Epub 2021 May 04.

BACKGROUND:  When emicizumab is dosed according to label, clinicians are obligated to discard or overdose medication due to discrepancies between calculated dose and vial content. The aim of this study was to compose a cost-efficient emicizumab maintenance dosing regimen...

Cite
Bukkems LH, Fischer K, Kremer-Hovinga I, et al. Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen. Thromb Haemost. 2021;doi: 10.1055/a-1499-0030.
Bukkems, L. H., Fischer, K., Kremer-Hovinga, I., Donners, A. A. M., Fijnvandraat, K., Schutgens, R. E. G., Cnossen, M. H., & Mathôt, R. A. A. (2021). Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen. Thrombosis and haemostasis, . https://doi.org/10.1055/a-1499-0030
Bukkems, Laura H, et al. "Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen." Thrombosis and haemostasis vol. (2021). doi: https://doi.org/10.1055/a-1499-0030
Bukkems LH, Fischer K, Kremer-Hovinga I, Donners AAM, Fijnvandraat K, Schutgens REG, Cnossen MH, Mathôt RAA. Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen. Thromb Haemost. 2021 May 04; doi: 10.1055/a-1499-0030. Epub 2021 May 04. PMID: 33946119.
Copy Download .nbib Format: NLM
Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors.

Research and practice in thrombosis and haemostasis

Li Z, Chen Z, Liu G, Cheng X, Yao W, Huang K, Li G, Zhen Y, Wu X, Cai S, Poon MC, Wu R.
PMID: 34278191
Res Pract Thromb Haemost. 2021 Jul 14;5(5):e12562. doi: 10.1002/rth2.12562. eCollection 2021 Jul.

BACKGROUND: In developing countries, children with hemophilia A (HA) with high-titer inhibitor and poor immune tolerance induction (ITI) prognostic risk(s) cannot afford the recommended high- or intermediate-dose ITI.OBJECTIVES: To determine the efficacy of low-dose ITI (plasma-derived factor VIII [FVIII]/von...

Cite
Li Z, Chen Z, Liu G, et al. Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors. Res Pract Thromb Haemost. 2021;5(5):e12562doi: 10.1002/rth2.12562.
Li, Z., Chen, Z., Liu, G., Cheng, X., Yao, W., Huang, K., Li, G., Zhen, Y., Wu, X., Cai, S., Poon, M. C., & Wu, R. (2021). Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors. Research and practice in thrombosis and haemostasis, 5(5), e12562. https://doi.org/10.1002/rth2.12562
Li, Zekun, et al. "Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors." Research and practice in thrombosis and haemostasis vol. 5,5 (2021): e12562. doi: https://doi.org/10.1002/rth2.12562
Li Z, Chen Z, Liu G, Cheng X, Yao W, Huang K, Li G, Zhen Y, Wu X, Cai S, Poon MC, Wu R. Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors. Res Pract Thromb Haemost. 2021 Jul 14;5(5):e12562. doi: 10.1002/rth2.12562. eCollection 2021 Jul. PMID: 34278191; PMCID: PMC8279128.
Copy Download .nbib Format: NLM
COVID-19 is Associated with an Acquired Factor XIII Deficiency.

Thrombosis and haemostasis

von Meijenfeldt FA, Havervall S, Adelmeijer J, Lundström A, Magnusson M, Mackman N, Thalin C, Lisman T.
PMID: 33742434
Thromb Haemost. 2021 Dec;121(12):1668-1669. doi: 10.1055/a-1450-8414. Epub 2021 Mar 19.

No abstract available.

Cite
von Meijenfeldt FA, Havervall S, Adelmeijer J, et al. COVID-19 is Associated with an Acquired Factor XIII Deficiency. Thromb Haemost. 2021;121(12):1668-1669doi: 10.1055/a-1450-8414.
von Meijenfeldt, F. A., Havervall, S., Adelmeijer, J., Lundström, A., Magnusson, M., Mackman, N., Thalin, C., & Lisman, T. (2021). COVID-19 is Associated with an Acquired Factor XIII Deficiency. Thrombosis and haemostasis, 121(12), 1668-1669. https://doi.org/10.1055/a-1450-8414
von Meijenfeldt, Fien A, et al. "COVID-19 is Associated with an Acquired Factor XIII Deficiency." Thrombosis and haemostasis vol. 121,12 (2021): 1668-1669. doi: https://doi.org/10.1055/a-1450-8414
von Meijenfeldt FA, Havervall S, Adelmeijer J, Lundström A, Magnusson M, Mackman N, Thalin C, Lisman T. COVID-19 is Associated with an Acquired Factor XIII Deficiency. Thromb Haemost. 2021 Dec;121(12):1668-1669. doi: 10.1055/a-1450-8414. Epub 2021 Mar 19. PMID: 33742434.
Copy Download .nbib Format: NLM
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban.

Journal of thrombosis and haemostasis : JTH

Bosch FTM, Mulder FI, Huisman MV, Zwicker JI, Di Nisio M, Carrier M, Segers A, Verhamme P, Middeldorp S, Weitz JI, Grosso MA, Duggal A, Büller HR, Wang TF, Garcia D, Kamphuisen PW, Raskob GE, van Es N.
PMID: 34455706
J Thromb Haemost. 2021 Dec;19(12):3008-3017. doi: 10.1111/jth.15516. Epub 2021 Sep 12.

BACKGROUND: In the Hokusai VTE Cancer study, the risk of major bleeding was 2.9% higher in the edoxaban group compared with the dalteparin group, mainly due to more gastrointestinal bleedings in patients with gastrointestinal cancer. The identification of risk...

Cite
Bosch FTM, Mulder FI, Huisman MV, et al. Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. J Thromb Haemost. 2021;19(12):3008-3017doi: 10.1111/jth.15516.
Bosch, F. T. M., Mulder, F. I., Huisman, M. V., Zwicker, J. I., Di Nisio, M., Carrier, M., Segers, A., Verhamme, P., Middeldorp, S., Weitz, J. I., Grosso, M. A., Duggal, A., Büller, H. R., Wang, T. F., Garcia, D., Kamphuisen, P. W., Raskob, G. E., & van Es, N. (2021). Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. Journal of thrombosis and haemostasis : JTH, 19(12), 3008-3017. https://doi.org/10.1111/jth.15516
Bosch, Floris T M, et al. "Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban." Journal of thrombosis and haemostasis : JTH vol. 19,12 (2021): 3008-3017. doi: https://doi.org/10.1111/jth.15516
Bosch FTM, Mulder FI, Huisman MV, Zwicker JI, Di Nisio M, Carrier M, Segers A, Verhamme P, Middeldorp S, Weitz JI, Grosso MA, Duggal A, Büller HR, Wang TF, Garcia D, Kamphuisen PW, Raskob GE, van Es N. Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. J Thromb Haemost. 2021 Dec;19(12):3008-3017. doi: 10.1111/jth.15516. Epub 2021 Sep 12. PMID: 34455706.
Copy Download .nbib Format: NLM
A mixed-methods study to evaluate a patient-designed tool to reduce harm from cancer-associated thrombosis: The EMPOWER study.

Research and practice in thrombosis and haemostasis

Baddeley E, Torrens-Burton A, Newman A, Nelson A, Pease N, Nelson R, Noble S.
PMID: 34401640
Res Pract Thromb Haemost. 2021 Aug 11;5(5):e12545. doi: 10.1002/rth2.12545. eCollection 2021 Jul.

INTRODUCTION: Venous thromboembolism (VTE) is a common and serious complication of systemic anticancer therapies. Delays in presentation increase risk of death or long-term morbidity.BACKGROUND: A patient charity developed an information video for patients receiving systemic anticancer therapy including what...

Cite
Baddeley E, Torrens-Burton A, Newman A, et al. A mixed-methods study to evaluate a patient-designed tool to reduce harm from cancer-associated thrombosis: The EMPOWER study. Res Pract Thromb Haemost. 2021;5(5):e12545doi: 10.1002/rth2.12545.
Baddeley, E., Torrens-Burton, A., Newman, A., Nelson, A., Pease, N., Nelson, R., & Noble, S. (2021). A mixed-methods study to evaluate a patient-designed tool to reduce harm from cancer-associated thrombosis: The EMPOWER study. Research and practice in thrombosis and haemostasis, 5(5), e12545. https://doi.org/10.1002/rth2.12545
Baddeley, Elin, et al. "A mixed-methods study to evaluate a patient-designed tool to reduce harm from cancer-associated thrombosis: The EMPOWER study." Research and practice in thrombosis and haemostasis vol. 5,5 (2021): e12545. doi: https://doi.org/10.1002/rth2.12545
Baddeley E, Torrens-Burton A, Newman A, Nelson A, Pease N, Nelson R, Noble S. A mixed-methods study to evaluate a patient-designed tool to reduce harm from cancer-associated thrombosis: The EMPOWER study. Res Pract Thromb Haemost. 2021 Aug 11;5(5):e12545. doi: 10.1002/rth2.12545. eCollection 2021 Jul. PMID: 34401640; PMCID: PMC8357625.
Copy Download .nbib Format: NLM
Showing 1297 to 1307 of 1307 entries